Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis
Indivior is a high-margin opioid-treatment turnaround: SUBLOCADE growth, buybacks, and margin expansion offer upside, but litigation risk keeps the valuation restrained.
Overview
Indivior is a focused specialty pharmaceutical turnaround built around SUBLOCADE, its once-monthly injectable buprenorphine therapy for opioid use disorder. The company has shifted away from declining legacy Suboxone Film and discontinued non-core products, concentrating resources on a high-growth, high-margin LAI franchise. SUBLOCADE now represents roughly 73% of revenue, with the U.S. as the dominant profit engine. Strong clinical utility, institutional adoption, and underpenetrated LAI markets support growth, while litigation and product concentration remain the central valuation overhangs.